Targeted therapies for EGFR (OMIM 131550)– and ALK (OMIM 105590)–altered metastatic non–small cell lung cancer (NSCLC) substantially improve outcomes for some patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.